Centessa Pharmaceuticals plc (NASDAQ:CNTA – Get Free Report) has received a consensus rating of “Buy” from the six brokerages that are currently covering the company, MarketBeat.com reports. Six equities research analysts have rated the stock with a buy recommendation. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $25.17.
A number of analysts have commented on the company. Morgan Stanley upgraded Centessa Pharmaceuticals from an “equal weight” rating to an “overweight” rating and upped their price target for the stock from $11.00 to $26.00 in a research report on Thursday, September 19th. B. Riley initiated coverage on shares of Centessa Pharmaceuticals in a research note on Thursday, September 19th. They set a “buy” rating and a $33.00 target price on the stock. BMO Capital Markets upped their price target on shares of Centessa Pharmaceuticals from $20.00 to $35.00 and gave the stock an “outperform” rating in a research report on Monday, September 16th. Guggenheim raised their price objective on shares of Centessa Pharmaceuticals from $20.00 to $24.00 and gave the company a “buy” rating in a research report on Wednesday, September 11th. Finally, Oppenheimer restated an “outperform” rating and set a $14.00 target price on shares of Centessa Pharmaceuticals in a research note on Wednesday, August 14th.
View Our Latest Report on CNTA
Insider Transactions at Centessa Pharmaceuticals
Institutional Investors Weigh In On Centessa Pharmaceuticals
A number of hedge funds have recently bought and sold shares of the business. Quarry LP bought a new stake in shares of Centessa Pharmaceuticals in the 4th quarter worth about $48,000. China Universal Asset Management Co. Ltd. raised its position in Centessa Pharmaceuticals by 69.2% during the first quarter. China Universal Asset Management Co. Ltd. now owns 10,817 shares of the company’s stock valued at $122,000 after purchasing an additional 4,423 shares during the period. Acadian Asset Management LLC purchased a new stake in Centessa Pharmaceuticals during the first quarter valued at approximately $330,000. Platinum Investment Management Ltd. lifted its stake in shares of Centessa Pharmaceuticals by 27.3% in the 1st quarter. Platinum Investment Management Ltd. now owns 485,174 shares of the company’s stock valued at $5,482,000 after purchasing an additional 104,091 shares during the last quarter. Finally, EntryPoint Capital LLC purchased a new position in shares of Centessa Pharmaceuticals in the 1st quarter worth approximately $109,000. Hedge funds and other institutional investors own 82.01% of the company’s stock.
Centessa Pharmaceuticals Stock Performance
CNTA opened at $16.05 on Monday. Centessa Pharmaceuticals has a 12-month low of $5.58 and a 12-month high of $17.59. The company has a market cap of $1.61 billion, a price-to-earnings ratio of -11.30 and a beta of 1.46. The company has a current ratio of 13.29, a quick ratio of 13.29 and a debt-to-equity ratio of 0.27. The company’s 50 day moving average is $14.69 and its 200 day moving average is $11.35.
Centessa Pharmaceuticals (NASDAQ:CNTA – Get Free Report) last issued its quarterly earnings results on Tuesday, August 13th. The company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.02). On average, equities research analysts predict that Centessa Pharmaceuticals will post -1.68 EPS for the current year.
About Centessa Pharmaceuticals
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.
Further Reading
- Five stocks we like better than Centessa Pharmaceuticals
- Where Do I Find 52-Week Highs and Lows?
- Is Spotify Stock Poised to Soar? Options Traders Think So
- What is the Hang Seng index?
- Misses and Beats: 3 Stocks That Are Moving Markets Right Now
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- Cisco on the Rise: AI Potential and Analyst Upgrades Drive Gains
Receive News & Ratings for Centessa Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Centessa Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.